Prognostic factors in acute myeloid leukaemia

被引：40

作者：

Löwenberg, B

机构：

[1] Erasmus Univ, NL-3000 CA Rotterdam, Netherlands

[2] Univ Rotterdam Hosp, NL-3000 CA Rotterdam, Netherlands

来源：

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2001年 / 14卷 / 01期

关键词：

prognosis; prognostic factors; acute myeloid leukaemia; cytogenetics; flt-3; receptor; mutations; molecular genetics;

D O I：

10.1053/beha.2000.0116

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The prognosis between subgroups of patients with acute myeloid leukaemia (AML) may range considerably. Haematological, genetic and clinical analysis has provided possibilities for defining the heterogeneity of prognosis. This furnishes clinically relevant insights into the probability of treatment response and survival in individual cases of AML and it provides a lead in treatment management.

引用

收藏

页码：65 / 75

页数：11

相关论文

共 59 条

[41]

Nakao M, 1996, LEUKEMIA, V10, P1911

[42] Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2αB gene associated with myeloblastic leukemias [J].

Osato, M ;

Asou, N ;

Abdalla, E ;

Hoshino, K ;

Yamasaki, H ;

Okubo, T ;

Suzushima, H ;

Takatsuki, K ;

Kanno, T ;

Shigesada, K ;

Ito, Y .

BLOOD, 1999, 93 (06) :1817-1824

[43] MYELOID NATURAL-KILLER-CELL ACUTE-LEUKEMIA - A PREVIOUSLY UNRECOGNIZED FORM OF ACUTE-LEUKEMIA POTENTIALLY MISDIAGNOSED AS FAB-M3 ACUTE MYELOID-LEUKEMIA [J].

PAIETTA, E ;

GALLAGHER, RE ;

WIERNIK, PH .

BLOOD, 1994, 84 (08) :2824-2825

[44] Human acute myeloid leukemia cells with internal tandem duplications in the Flt3 gene show reduced proliferative ability in stroma supported long-term cultures [J].

Rombouts, WJC ;

Broyl, A ;

Martens, ACM ;

Slater, R ;

Ploemacher, RE .

LEUKEMIA, 1999, 13 (07) :1071-1078

[45] Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene [J].

Rombouts, WJC ;

Blokland, I ;

Löwenberg, B ;

Ploemacher, RE .

LEUKEMIA, 2000, 14 (04) :675-683

[46] Immunophenotyping of AML and MDS and detection of residual disease [J].

Sanz, MA ;

Sempere, A .

BAILLIERES CLINICAL HAEMATOLOGY, 1996, 9 (01) :35-55

[47] EXPRESSION OF THE MULTIDRUG RESISTANCE GENE IN MYELOID LEUKEMIAS [J].

SATO, H ;

GOTTESMAN, MM ;

GOLDSTEIN, LJ ;

PASTAN, I ;

BLOCK, AM ;

SANDBERG, AA ;

PREISLER, HD .

LEUKEMIA RESEARCH, 1990, 14 (01) :11-&

[48] Expression of the c-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance [J].

Schwartz, S ;

Heinecke, A ;

Zimmermann, M ;

Creutzig, U ;

Schoch, C ;

Harbott, J ;

Fonatsch, C ;

Löffler, H ;

Büchner, T ;

Ludwig, WD ;

Thiel, E .

LEUKEMIA & LYMPHOMA, 1999, 34 (1-2) :85-94

[49]

SEGEREN CM, 1995, ANN HEMATOL, V70, P297, DOI 10.1007/BF01696615

[50] ANALYSIS OF TREATMENT FAILURE IN PATIENTS WITH MINIMALLY DIFFERENTIATED ACUTE MYELOID-LEUKEMIA (AML-MO) [J].

STASI, R ;

DELPOETA, G ;

VENDITTI, A ;

MASI, M ;

STIPA, E ;

DENTAMARO, T ;

COX, C ;

DALLAPICCOLA, B ;

PAPA, G .

BLOOD, 1994, 83 (06) :1619-1625

← 1 2 3 4 5 6 →